{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:42:57Z","timestamp":1789173777285,"version":"build-2803163510"},"update-to":[{"DOI":"10.1371\/journal.ppat.1013245","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000}}],"reference-count":72,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1066973, OPP1146433"],"award-info":[{"award-number":["OPP1066973, OPP1146433"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-055901"],"award-info":[{"award-number":["INV-055901"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["TMA2020CDF-3183"],"award-info":[{"award-number":["TMA2020CDF-3183"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Research Foundation Thuthuka Program","award":["129653"],"award-info":[{"award-number":["129653"]}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["00406"],"award-info":[{"award-number":["00406"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000866","name":"International AIDS Vaccine Initiative","doi-asserted-by":"publisher","award":["UKZNRSA1001"],"award-info":[{"award-number":["UKZNRSA1001"]}],"id":[{"id":"10.13039\/100000866","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["R37AI067073"],"award-info":[{"award-number":["R37AI067073"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Witten Family Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Dan and Marjorie Sullivan Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Mark and Lisa Schwartz Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Ursula Brunner","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100002554","name":"AIDS Healthcare Foundation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100002554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007301","name":"Harvard University Center for AIDS Research","doi-asserted-by":"publisher","award":["P30AI060354"],"award-info":[{"award-number":["P30AI060354"]}],"id":[{"id":"10.13039\/100007301","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sub-Saharan African Network for TB & HIV Research Excellence (SANTHE) funded by Science for Africa Foundation","award":["DEL-22-007"],"award-info":[{"award-number":["DEL-22-007"]}]},{"name":"Sub-Saharan African Network for TB & HIV Research Excellence (SANTHE) funded by Bill and Melinda Gates Foundation","award":["INV033558"],"award-info":[{"award-number":["INV033558"]}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["19275"],"award-info":[{"award-number":["19275"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"abstract":"<jats:p>Broadly neutralizing antibodies (bnAbs), passively administered or elicited through vaccination, are a promising strategy for novel HIV prevention, treatment or inducing ART-free remission. However, HIV diversity and evolution are a barrier to the efficacy of bnAbs and there is therefore an urgent need for continuous virus surveillance to identify bnAbs with optimal neutralization breadth and potency against transmitted\/founder (TF) viruses, especially in high-burden regions. We determined the neutralization sensitivity of TF viruses isolated within seven days after first detection of heterosexually acquired infection from young women 18\u201323 years old (n\u2009=\u200939) and within 1 month after birth from in-utero infected infants (n\u2009=\u200921) from FRESH and Baby Cure cohorts respectively, in KwaZulu-Natal, South Africa, where HIV-1 subtype C predominates. Neutralization sensitivities of 47 viruses from FRESH and 21 viruses from Baby Cure were assessed against nine bnAbs targeting different regions on the HIV-1 Env trimer. HIV-1 <jats:italic>env<\/jats:italic> sequences within and between bnAb epitopes were compared with database. The bnAbs VRC07\u2013523LS, CAP256-VRC26.25, PGDM1400, 10E8 and PGT151 displayed higher neutralization breadth and potency than other bnAbs against FRESH TF viruses (&gt;70% coverage, starting concentration of 10 \u03bcg\/ml). Furthermore, VRC07\u2013523LS showed higher neutralization breadth and potency than other bnAbs against Baby Cure TF viruses (p\u2009=\u20090.02). Interestingly, CAP256-VRC26.25 and PGT151 had lower neutralization coverage against infant TF viruses (&lt;60% coverage). Moreover, 40% of infants TF had escape mutations within the V2 loop compared to 28% observed in FRESH and these mutations may explain the observed differences in neutralization sensitivities. However, few mutations were observed in gp120-gp41 interface in both adults and infants. Our findings suggest that intervention studies may have to consider different antibody combinations in adult versus paediatric settings. Moreover, high transmission of escape variants in both vertical and heterosexual transmissions is of concern. This information may be important in the selection of bnAbs that will undergo clinical testing in subtype C settings.<\/jats:p>","DOI":"10.1371\/journal.ppat.1013245","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T17:47:16Z","timestamp":1750700836000},"page":"e1013245","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Distinct neutralization sensitivity between adult and infant transmitted\/founder HIV-1 subtype C viruses to broadly neutralizing monoclonal antibodies"],"prefix":"10.1371","volume":"21","author":[{"given":"Bongiwe","family":"Ndlovu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamini","family":"Gounder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelisiwe","family":"Zikhali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanish","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ntokozo","family":"Ntshangase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nombali","family":"Gumede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Millar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca T.","family":"van Dorsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas E.","family":"Grayson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bonsall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra E.","family":"Chaudron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Mabuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista L.","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny L.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.R.","family":"Goulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2962-3992","authenticated-orcid":true,"given":"Thumbi","family":"Ndung\u2019u","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"ppat.1013245.ref001","unstructured":"UNAIDS. Joint United Nations Programme on HIV\/AIDS. UNAIDS Global HIV\/AIDS Report. 2022."},{"issue":"9","key":"ppat.1013245.ref002","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S1473-3099(14)70847-3","article-title":"Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study","volume":"14","author":"RM Grant","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"ppat.1013245.ref003","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1001\/jamainternmed.2015.4683","article-title":"Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services","volume":"176","author":"AY Liu","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"10","key":"ppat.1013245.ref004","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/cid\/cix593","article-title":"Redefining Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis Failures","volume":"65","author":"JL Marcus","year":"2017","journal-title":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America"},{"key":"ppat.1013245.ref005","doi-asserted-by":"crossref","DOI":"10.1097\/QAI.0000000000002200","article-title":"Getting to Zero San Francisco: A Collective Impact Approach","volume":"82","author":"SP Buchbinder","year":"2019","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"issue":"7475","key":"ppat.1013245.ref006","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nature12746","article-title":"Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia","volume":"503","author":"M Shingai","year":"2013","journal-title":"Nature"},{"issue":"408","key":"ppat.1013245.ref007","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao4235","article-title":"Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail","volume":"9","author":"B Julg","year":"2017","journal-title":"Science Translational Medicine"},{"issue":"3","key":"ppat.1013245.ref008","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2019.08.014","article-title":"A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge","volume":"26","author":"A Pegu","year":"2019","journal-title":"Cell Host Microbe"},{"issue":"10","key":"ppat.1013245.ref009","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1097\/QAD.0000000000002934","article-title":"Broadly neutralizing antibody-mediated protection of macaques against repeated intravenous exposures to simian-human immunodeficiency virus","volume":"35","author":"DA Garber","year":"2021","journal-title":"AIDS"},{"issue":"7557","key":"ppat.1013245.ref010","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"M Caskey","year":"2015","journal-title":"Nature"},{"issue":"7613","key":"ppat.1013245.ref011","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature18929","article-title":"HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption","volume":"535","author":"JF Scheid","year":"2016","journal-title":"Nature"},{"issue":"4","key":"ppat.1013245.ref012","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41591-019-0412-8","article-title":"Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic","volume":"25","author":"M Caskey","year":"2019","journal-title":"Nature Medicine"},{"issue":"2","key":"ppat.1013245.ref013","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/72309","article-title":"Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection","volume":"6","author":"TW Baba","year":"2000","journal-title":"Nat Med"},{"issue":"7427","key":"ppat.1013245.ref014","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature11604","article-title":"HIV therapy by a combination of broadly neutralizing antibodies in humanized mice","volume":"492","author":"F Klein","year":"2012","journal-title":"Nature"},{"issue":"4","key":"ppat.1013245.ref015","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/infdis\/jiw203","article-title":"Protection of Humanized Mice From Repeated Intravaginal HIV Challenge by Passive Immunization: A Model for Studying the Efficacy of Neutralizing Antibodies In Vivo","volume":"214","author":"M Deruaz","year":"2016","journal-title":"J Infect Dis"},{"issue":"9","key":"ppat.1013245.ref016","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1007\/s00705-016-2942-4","article-title":"VRC01 antibody protects against vaginal and rectal transmission of human immunodeficiency virus 1 in hu-BLT mice","volume":"161","author":"M Sun","year":"2016","journal-title":"Arch Virol"},{"issue":"1","key":"ppat.1013245.ref017","doi-asserted-by":"crossref","first-page":"1845908","DOI":"10.1080\/19420862.2020.1845908","article-title":"Diverse HIV-1 escape pathways from broadly neutralizing antibody PGDM1400 in humanized mice","volume":"12","author":"YU van der Velden","year":"2020","journal-title":"mAbs"},{"issue":"2","key":"ppat.1013245.ref018","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"M Caskey","year":"2017","journal-title":"Nature Medicine"},{"issue":"319","key":"ppat.1013245.ref019","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad5752","article-title":"Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection","volume":"7","author":"RM Lynch","year":"2015","journal-title":"Sci Transl Med"},{"issue":"3","key":"ppat.1013245.ref020","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/cei.12692","article-title":"Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults","volume":"182","author":"JE Ledgerwood","year":"2015","journal-title":"Clin Exp Immunol"},{"issue":"11","key":"ppat.1013245.ref021","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41591-018-0186-4","article-title":"Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals","volume":"24","author":"Y Bar-On","year":"2018","journal-title":"Nat Med"},{"issue":"21","key":"ppat.1013245.ref022","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","article-title":"Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption","volume":"375","author":"KJ Bar","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"ppat.1013245.ref023","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","article-title":"Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition","volume":"384","author":"L Corey","year":"2021","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"ppat.1013245.ref024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005520","article-title":"Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection","volume":"12","author":"K Wagh","year":"2016","journal-title":"PLoS Pathog"},{"issue":"6","key":"ppat.1013245.ref025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011469","article-title":"Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials","volume":"19","author":"NN Mkhize","year":"2023","journal-title":"PLoS Pathog"},{"issue":"3","key":"ppat.1013245.ref026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005520","article-title":"Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection","volume":"12","author":"K Wagh","year":"2016","journal-title":"PLoS Pathog"},{"issue":"5","key":"ppat.1013245.ref027","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1128\/JVI.03136-14","article-title":"Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes","volume":"89","author":"R Kong","year":"2015","journal-title":"J Virol"},{"issue":"7","key":"ppat.1013245.ref028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005742","article-title":"Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization","volume":"12","author":"C Rademeyer","year":"2016","journal-title":"PLoS Pathog"},{"issue":"1","key":"ppat.1013245.ref029","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12977-021-00556-2","article-title":"Neutralization diversity of HIV-1 Indian subtype C envelopes obtained from cross sectional and followed up individuals against broadly neutralizing monoclonal antibodies having distinct gp120 specificities","volume":"18","author":"R Mullick","year":"2021","journal-title":"Retrovirology"},{"issue":"9","key":"ppat.1013245.ref030","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/nm.2203","article-title":"Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level","volume":"16","author":"EM Bunnik","year":"2010","journal-title":"Nat Med"},{"issue":"6929","key":"ppat.1013245.ref031","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature01470","article-title":"Antibody neutralization and escape by HIV-1","volume":"422","author":"X Wei","year":"2003","journal-title":"Nature"},{"issue":"3","key":"ppat.1013245.ref032","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1128\/JVI.01839-06","article-title":"Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection","volume":"81","author":"R Rong","year":"2007","journal-title":"J Virol"},{"issue":"11","key":"ppat.1013245.ref033","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1038\/nm.2985","article-title":"Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape","volume":"18","author":"PL Moore","year":"2012","journal-title":"Nature Medicine"},{"issue":"24","key":"ppat.1013245.ref034","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01270-22","article-title":"Subtle Longitudinal Alterations in Env Sequence Potentiate Differences in Sensitivity to Broadly Neutralizing Antibodies following Acute HIV-1 Subtype C Infection","volume":"96","author":"T Mandizvo","year":"2022","journal-title":"J Virol"},{"key":"ppat.1013245.ref035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2020.03.003","article-title":"Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infection","volume":"546","author":"B Ndlovu","year":"2020","journal-title":"Virology"},{"key":"ppat.1013245.ref036","doi-asserted-by":"crossref","first-page":"757400","DOI":"10.3389\/fimmu.2021.757400","article-title":"Understanding Viral and Immune Interplay During Vertical Transmission of HIV: Implications for Cure","volume":"12","author":"O Amin","year":"2021","journal-title":"Front Immunol"},{"issue":"10","key":"ppat.1013245.ref037","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1128\/JVI.75.10.4780-4791.2001","article-title":"Cell-to-cell contact results in a selective translocation of maternal human immunodeficiency virus type 1 quasispecies across a trophoblastic barrier by both transcytosis and infection","volume":"75","author":"S Lagaye","year":"2001","journal-title":"J Virol"},{"key":"ppat.1013245.ref038","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1742-4690-6-46","article-title":"Proteasome-independent degradation of HIV-1 in naturally non-permissive human placental trophoblast cells","volume":"6","author":"AL Ross","year":"2009","journal-title":"Retrovirology"},{"issue":"13","key":"ppat.1013245.ref039","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.03.016","article-title":"Endogenous Retroviral Envelope Syncytin Induces HIV-1 Spreading and Establishes HIV Reservoirs in Placenta","volume":"30","author":"Y Tang","year":"2020","journal-title":"Cell Rep"},{"issue":"4","key":"ppat.1013245.ref040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009478","article-title":"Mutations that confer resistance to broadly-neutralizing antibodies define HIV-1 variants of transmitting mothers from that of non-transmitting mothers","volume":"17","author":"A Kumar","year":"2021","journal-title":"PLoS Pathog"},{"issue":"7","key":"ppat.1013245.ref041","article-title":"Capacity of broadly neutralizing antibodies to inhibit HIV-1 cell-cell transmission is strain- and epitope-dependent","volume":"11","author":"L Reh","year":"2015","journal-title":"PLoS Pathog"},{"issue":"4","key":"ppat.1013245.ref042","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002634","article-title":"Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies","volume":"8","author":"IA Abela","year":"2012","journal-title":"PLoS Pathog"},{"issue":"6","key":"ppat.1013245.ref043","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nm.3565","article-title":"Early development of broadly neutralizing antibodies in HIV-1-infected infants","volume":"20","author":"L Goo","year":"2014","journal-title":"Nat Med"},{"issue":"358","key":"ppat.1013245.ref044","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag1048","article-title":"Nonprogressing HIV-infected children share fundamental immunological features of nonpathogenic SIV infection","volume":"8","author":"M Muenchhoff","year":"2016","journal-title":"Sci Transl Med"},{"issue":"17","key":"ppat.1013245.ref045","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00878-18","article-title":"HIV-1 subtype C-infected children with exceptional neutralization breadth exhibit polyclonal responses targeting known epitopes","volume":"92","author":"Z Ditse","year":"2018","journal-title":"J Virol"},{"issue":"1","key":"ppat.1013245.ref046","article-title":"Detection and treatment of Fiebig stage I HIV-1 infection in young at-risk women in South Africa: a prospective cohort study","volume":"5","author":"KL Dong","year":"2018","journal-title":"Lancet HIV"},{"issue":"27","key":"ppat.1013245.ref047","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aau2798","article-title":"A fresh approach: Combining basic science and social good","volume":"3","author":"T Ndung\u2019u","year":"2018","journal-title":"Science Immunology"},{"key":"ppat.1013245.ref048","doi-asserted-by":"crossref","first-page":"100344","DOI":"10.1016\/j.eclinm.2020.100344","article-title":"High-frequency failure of combination antiretroviral therapy in paediatric HIV infection is associated with unmet maternal needs causing maternal NON-ADHERENCE","volume":"22","author":"JR Millar","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"4","key":"ppat.1013245.ref049","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006944","article-title":"Infant transmitted\/founder HIV-1 viruses from peripartum transmission are neutralization resistant to paired maternal plasma","volume":"14","author":"A Kumar","year":"2018","journal-title":"PLoS Pathog"},{"issue":"10","key":"ppat.1013245.ref050","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00382-20","article-title":"A Comprehensive Genomics Solution for HIV Surveillance and Clinical Monitoring in Low-Income Settings","volume":"58","author":"D Bonsall","year":"2020","journal-title":"J Clin Microbiol"},{"issue":"5666","key":"ppat.1013245.ref051","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1126\/science.1093137","article-title":"Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission","volume":"303","author":"CA Derdeyn","year":"2004","journal-title":"Science"},{"issue":"11","key":"ppat.1013245.ref052","article-title":"HIV transmission","volume":"2","author":"GM Shaw","year":"2012","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"issue":"1","key":"ppat.1013245.ref053","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12977-017-0343-8","article-title":"The HIV-1 transmission bottleneck","volume":"14","author":"SM Kariuki","year":"2017","journal-title":"Retrovirology"},{"issue":"6193","key":"ppat.1013245.ref054","doi-asserted-by":"crossref","first-page":"1254031","DOI":"10.1126\/science.1254031","volume":"345","author":"JM Carlson","year":"2014","journal-title":"Science"},{"issue":"12","key":"ppat.1013245.ref055","doi-asserted-by":"crossref","first-page":"8118","DOI":"10.1128\/jvi.69.12.8118-8122.1995","article-title":"Diversity in virus populations from genital secretions and peripheral blood from women recently infected with human immunodeficiency virus type 1","volume":"69","author":"M Poss","year":"1995","journal-title":"J Virol"},{"issue":"21","key":"ppat.1013245.ref056","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.1073\/pnas.0802203105","article-title":"Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection","volume":"105","author":"BF Keele","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"ppat.1013245.ref057","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1084\/jem.20090378","article-title":"Genetic identity, biological phenotype, and evolutionary pathways of transmitted\/founder viruses in acute and early HIV-1 infection","volume":"206","author":"JF Salazar-Gonzalez","year":"2009","journal-title":"J Exp Med"},{"issue":"17","key":"ppat.1013245.ref058","doi-asserted-by":"crossref","first-page":"8925","DOI":"10.1128\/JVI.00758-09","article-title":"Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors","volume":"83","author":"ES Gray","year":"2009","journal-title":"J Virol"},{"key":"ppat.1013245.ref059","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/978-1-59745-170-3_26","article-title":"Measuring HIV neutralization in a luciferase reporter gene assay","volume":"485","author":"DC Montefiori","year":"2009","journal-title":"Methods Mol Biol"},{"issue":"6","key":"ppat.1013245.ref060","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1084\/jem.20130221","article-title":"Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies","volume":"210","author":"R Diskin","year":"2013","journal-title":"J Exp Med"},{"issue":"1","key":"ppat.1013245.ref061","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2018.12.001","article-title":"HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design","volume":"25","author":"CA Bricault","year":"2019","journal-title":"Cell Host & Microbe"},{"issue":"1","key":"ppat.1013245.ref062","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1128\/JVI.01791-15","article-title":"New member of the V1V2-directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency","volume":"90","author":"NA Doria-Rose","year":"2016","journal-title":"J Virol"},{"issue":"236","key":"ppat.1013245.ref063","article-title":"Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV","volume":"6","author":"D Sok","year":"2014","journal-title":"Sci Transl Med"},{"issue":"19","key":"ppat.1013245.ref064","doi-asserted-by":"crossref","first-page":"10724","DOI":"10.1128\/JVI.78.19.10724-10737.2004","article-title":"Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope","volume":"78","author":"G Ofek","year":"2004","journal-title":"J Virol"},{"issue":"7","key":"ppat.1013245.ref065","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aal2200","article-title":"Potent and broad HIV-neutralizing antibodies in memory B cells and plasma","volume":"2","author":"LD Williams","year":"2017","journal-title":"Sci Immunol"},{"issue":"5","key":"ppat.1013245.ref066","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.immuni.2014.04.008","article-title":"Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers","volume":"40","author":"C Blattner","year":"2014","journal-title":"Immunity"},{"issue":"7","key":"ppat.1013245.ref067","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005742","article-title":"Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization","volume":"12","author":"C Rademeyer","year":"2016","journal-title":"PLoS Pathog"},{"issue":"9","key":"ppat.1013245.ref068","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02422-16","article-title":"Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk","volume":"91","author":"DR Martinez","year":"2017","journal-title":"J Virol"},{"issue":"2","key":"ppat.1013245.ref069","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00176-20","article-title":"Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted\/Founder HIV Variants","volume":"11","author":"DR Martinez","year":"2020","journal-title":"mBio"},{"issue":"7","key":"ppat.1013245.ref070","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1172\/JCI81593","article-title":"Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission","volume":"125","author":"SR Permar","year":"2015","journal-title":"J Clin Invest"},{"issue":"1","key":"ppat.1013245.ref071","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12977-017-0331-z","article-title":"Breast milk and in utero transmission of HIV-1 select for envelope variants with unique molecular signatures","volume":"14","author":"KJ Nakamura","year":"2017","journal-title":"Retrovirology"},{"issue":"2","key":"ppat.1013245.ref072","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1128\/JVI.80.2.835-844.2006","article-title":"Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant","volume":"80","author":"X Wu","year":"2006","journal-title":"J Virol"}],"updated-by":[{"DOI":"10.1371\/journal.ppat.1013245","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000}}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1013245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T17:55:23Z","timestamp":1751565323000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1013245"}},"subtitle":[],"editor":[{"given":"R. Keith","family":"Reeves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":72,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1013245","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.ppat.1013245","asserted-by":"object"}]},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]}}}